NCT03387475View on ClinicalTrials.gov

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Myelodysplasia
Interventions
DRUG

Deferasirox

iron chelation

Trial Locations (1)

38043

CHU de GRENOBLE ALPES, Grenoble

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Hospital, Grenoble

OTHER